Radiopharm Theranostics (RADX) Stock Price, Quote, News & History

Key Statistics

Open

$4.87

$4.90

Volume / Avg.

37.47K / 713.80K

Day Range

$4.84 - $4.97

52 Wk Range

3.50 - 16.25

Market Cap

$37.73M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.51%

Days to Cover

1.01

Recent Radiopharm Theranostics Ltd News

Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga Senior Editor

Dow Falls 50 Points; US Adds 64,000 Jobs In November

Avi Kapoor

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

Investing Cash Flow (TTM)

1.77M

Financing Cash Flow (TTM)

45.43M

Free Cash Flow (TTM)

-36.65M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

10.56M

Analyst Trends and Forecast

Nov 25

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$14.21M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

15.40

PB Ratio (TTM)

1.25

Earnings Yield % (TTM)

-74.41%

Earnings Yield % (FWD)

-42.83%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$4.02

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$1.90M

Total Cash

$36.44M

Debt to Equity

Issuance of Debt (TTM)

-$1.90M

Repayment of Debt (TTM)

-$1.90M

Key Statistics

Open

$4.87

$4.90

Volume / Avg.

37.47K / 713.80K

Day Range

$4.84 - $4.97

52 Wk Range

3.50 - 16.25

Market Cap

$37.73M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.51%

Days to Cover

1.01

About

Sector

Health Care

Industry

Biotechnology

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pr...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry